Article summary
The European Medicines Agency (EMA) has published a Q&A on the interchangeability of biosimilar medicines, that contain active substances from a biological source, across the EU. EMA provides information for patients and healthcare professionals, as well an overview of biosimilar development and approval in the EU and regulatory guidance.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial